Givosiran ENVISION Phase 3 Clinical Trial Overview

ENVISION

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias (AHPs)

Study Objective

Evaluate the effect of subcutaneous givosiran compared to placebo, on the rate of porphyria attacks in patients with AHPs.

ENVISION Design

- The global, multicenter trial is enrolling approximately 75 patients, age 12 or older, with AHPs at clinical centers in more than 20 countries worldwide.
- Study participants may be randomly assigned to receive givosiran 2.5 mg/kg or placebo subcutaneously administered once monthly over a six-month treatment period.
- A planned interim analysis, agreed upon with the Food and Drug Administration (FDA), will evaluate reduction in biomarker levels - aminolevulinic acid (ALA) - that may reasonably predict clinical benefit. Reduction in ALA will be evaluated in 30 patients after three months of dosing.
- All patients completing the six-month treatment period, with either givosiran or placebo, may be eligible to continue on an open-label extension (OLE) study in which they will receive treatment with givosiran for up to 30 months.

ENVISION Endpoints

- The primary endpoint is the annualized rate of porphyria attacks over six months.
- Secondary endpoints will evaluate the impact of givosiran on reducing chronic symptoms of AHPs, such as pain, nausea, and fatigue, that impact daily functioning and quality of life.

Planned ENVISION Development Timeline

Early 2018

Phase 3 study initiated in November 2017

Mid 2018

Phase 3 Interim Analysis Topline

Late 2018

New Drug Application Filed in the U.S.

Complete Phase 3 Enrollment

Early is Q1-Q2, Mid is Q2-Q3, and Late is Q3-Q4

Fast Facts About AHPs

- Family of rare, genetic diseases characterized by potentially life-threatening attacks and, for many patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life.
- Common symptoms include severe, diffuse abdominal pain, weakness, nausea, and fatigue.
- Currently, there are no treatments approved to prevent debilitating attacks and treat the chronic symptoms of the disease.

About Givosiran

Givosiran (ALN-AS1) is an investigational, subcutaneously administered RNA interference (RNAi) therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of AHPs.

For more information, please visit ENVISIONclinicaltrial.com or contact media@alnylam.com.